<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Immunology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-3224</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9315150</article-id>
    <article-id pub-id-type="doi">10.3389/fimmu.2022.931155</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Immunology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SARS-Arena: Sequence and Structure-Guided Selection of Conserved Peptides from SARS-related Coronaviruses for Novel Vaccine Development</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Rigo</surname>
          <given-names>Mauricio Menegatti</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1307290"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fasoulis</surname>
          <given-names>Romanos</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1883269"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Conev</surname>
          <given-names>Anja</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1882842"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hall-Swan</surname>
          <given-names>Sarah</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1885455"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Antunes</surname>
          <given-names>Dinler Amaral</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/420724"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Kavraki</surname>
          <given-names>Lydia E.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <xref rid="fn003" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/136640"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Kavraki Lab, Department of Computer Science, Rice University</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Antunes Lab, Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Pieter Meysman, University of Antwerp, Belgium</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Debmalya Barh, Institute of Integrative Omics and Applied Biotechnology (IIOAB), India; Anam Naz, University of Lahore, Pakistan</p>
      </fn>
      <corresp id="fn001">*Correspondence: Lydia E. Kavraki, <email xlink:href="mailto:kavraki@rice.edu">kavraki@rice.edu</email>; Dinler Amaral Antunes, <email xlink:href="mailto:dinler@uh.edu">dinler@uh.edu</email>
</corresp>
      <fn fn-type="other" id="fn003">
        <p>†ORCID: Mauricio Menegatti Rigo, <uri xlink:href="https://orcid.org/0000-0002-1584-6194">orcid.org/0000-0002-1584-6194</uri>; Romanos Fasoulis, <uri xlink:href="https://orcid.org/0000-0001-7106-6689">orcid.org/0000-0001-7106-6689</uri>; Anja Conev, <uri xlink:href="https://orcid.org/0000-0001-9049-0266">orcid.org/0000-0001-9049-0266</uri>; Sarah Hall-Swan, <uri xlink:href="https://orcid.org/0000-0003-1030-0392">orcid.org/0000-0003-1030-0392</uri>; Dinler Amaral Antunes, <uri xlink:href="https://orcid.org/0000-0001-7947-6455">orcid.org/0000-0001-7947-6455</uri>; Lydia Kavraki, <uri xlink:href="https://orcid.org/0000-0003-0699-8038">orcid.org/0000-0003-0699-8038</uri>
</p>
      </fn>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>7</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>7</month>
      <year>2022</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>13</volume>
    <elocation-id>931155</elocation-id>
    <history>
      <date date-type="received">
        <day>28</day>
        <month>4</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>10</day>
        <month>6</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Rigo, Fasoulis, Conev, Hall-Swan, Antunes and Kavraki</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Rigo, Fasoulis, Conev, Hall-Swan, Antunes and Kavraki</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>The pandemic caused by the SARS-CoV-2 virus, the agent responsible for the COVID-19 disease, has affected millions of people worldwide. There is constant search for new therapies to either prevent or mitigate the disease. Fortunately, we have observed the successful development of multiple vaccines. Most of them are focused on one viral envelope protein, the spike protein. However, such focused approaches may contribute for the rise of new variants, fueled by the constant selection pressure on envelope proteins, and the widespread dispersion of coronaviruses in nature. Therefore, it is important to examine other proteins, preferentially those that are less susceptible to selection pressure, such as the nucleocapsid (N) protein. Even though the N protein is less accessible to humoral response, peptides from its conserved regions can be presented by class I Human Leukocyte Antigen (HLA) molecules, eliciting an immune response mediated by T-cells. Given the increased number of protein sequences deposited in biological databases daily and the N protein conservation among viral strains, computational methods can be leveraged to discover potential new targets for SARS-CoV-2 and SARS-CoV-related viruses. Here we developed SARS-Arena, a user-friendly computational pipeline that can be used by practitioners of different levels of expertise for novel vaccine development. SARS-Arena combines sequence-based methods and structure-based analyses to (i) perform multiple sequence alignment (MSA) of SARS-CoV-related N protein sequences, (ii) recover candidate peptides of different lengths from conserved protein regions, and (iii) model the 3D structure of the conserved peptides in the context of different HLAs. We present two main Jupyter Notebook workflows that can help in the identification of new T-cell targets against SARS-CoV viruses. In fact, in a cross-reactive case study, our workflows identified a conserved N protein peptide (SPRWYFYYL) recognized by CD8<sup>+</sup> T-cells in the context of HLA-B7<sup>+</sup>. SARS-Arena is available at <uri xlink:href="https://github.com/KavrakiLab/SARS-Arena">https://github.com/KavrakiLab/SARS-Arena</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>SARS-CoV-2</kwd>
      <kwd>SARS-CoV</kwd>
      <kwd>protein sequence alignment</kwd>
      <kwd>structural modeling</kwd>
      <kwd>HLA-Arena</kwd>
      <kwd>nucleocapsid protein</kwd>
      <kwd>pHLA scoring</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">
          <institution-wrap>
            <institution>National Science Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/100000001</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="4"/>
      <table-count count="2"/>
      <equation-count count="0"/>
      <ref-count count="63"/>
      <page-count count="10"/>
      <word-count count="5342"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>1 Introduction</title>
    <p>In 2003, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused a pandemic that resulted in more than 8,096 cases and 774 deaths (<xref rid="B1" ref-type="bibr">1</xref>). This was not the first time coronaviruses cause epidemics in humans, and multiple strains of coronaviruses have been identified in bats and other organisms, serving as a warning about the risks for a new epidemic (<xref rid="B2" ref-type="bibr">2</xref>). Unfortunately, acknowledging the presence of circulating coronaviruses was not sufficient to avoid the current pandemic, caused by a novel strain of coronavirus called SARS-CoV-2 (<xref rid="B3" ref-type="bibr">3</xref>). SARS-CoV-2 is the etiologic agent responsible for the COVID-19 disease in humans. This new variant was identified at the end of 2019 and quickly spread to a pandemic level during the first months of 2020. The consequences of COVID-19 have been disastrous, both to individual health as well as to the economy (<xref rid="B4" ref-type="bibr">4</xref>). Massive vaccination campaigns across different countries have been crucial to helping the mitigation of COVID-19. However, the large reservoir of SARS-type viruses in the wild, and the well-known capacity of coronaviruses to undergo genetic recombination, highlights the continued risk for new pandemics in the future (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Therefore, there is a need for effective vaccination strategies that would protect individuals against a broad range of SARS-like coronaviruses.</p>
    <p>Because of the inverse correlation of protection between neutralizing antibodies and SARS-CoV-2 viral load (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>), envelope proteins - such as the spike (S) protein, have been used as the main target on currently approved human vaccines. However, envelope proteins are known to be more susceptible to selection pressure in comparison to inner viral proteins, and therefore more prone to mutations that can lead to resistance to treatment and decreased vaccine efficacy. During the SARS-CoV-2 pandemic, we did observe cases that led to an increase of infectiousness (e.g., D614G mutation) or transmissibility (e.g., B.1.1.7 variant, also called Alpha variant) (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>) driven mainly by mutations in envelope proteins. The variant B.1.617 (also called Delta variant), containing pivotal mutations on the S protein, rapidly became the dominant strain in several countries during 2021. The B.1.1.529 variant, named the Omicron variant, has more than 30 new mutations in the S protein and these mutations may contribute to improved infectiousness of SARS-CoV-2 (<xref rid="B11" ref-type="bibr">11</xref>). In other words, even with successful vaccines developed for SARS-CoV-2, it is unclear for how long the efficacy will persist. This is highlighted by a recent WHO statement on the need of updating current vaccines (<uri xlink:href="https://www.who.int/news/">https://www.who.int/news/</uri>).</p>
    <p>Apart from the development of a strong humoral response (e.g., neutralizing antibodies), vaccination strategies also have to induce a protective, long-term, cell-mediated immunity (i.e., based on T-cell lymphocytes). Reports on SARS-related coronaviruses have shown that SARS-CoV-specific antibodies can significantly drop in the first 2 to 3 years after infection (<xref rid="B12" ref-type="bibr">12</xref>), while the SARS-CoV-specific T-cells can persist for more than a decade (<xref rid="B13" ref-type="bibr">13</xref>). T-cells recognize peptides displayed at the surface of infected cells by class I Human Leukocyte Antigens (HLAs). Therefore, peptide-based vaccines aiming at triggering T-cells can target any viral protein, and proteins with lower mutation rates in respect to envelope proteins would represent promising targets for broad-spectrum vaccine development (<xref rid="B14" ref-type="bibr">14</xref>).</p>
    <p>One of these proteins is the nucleocapsid (N) protein. The N protein is a promising target for a multitude of reasons. Firstly, this protein is highly conserved even across different coronaviruses (<xref rid="B15" ref-type="bibr">15</xref>) and is highly immunogenic and expressed during the infection course (<xref rid="B16" ref-type="bibr">16</xref>). Moreover, it presents a low mutation rate compared to envelope proteins, mainly because this protein is not exposed on the surface of the virus and hence is less impacted by the antibody-mediated selective pressure (<xref rid="B17" ref-type="bibr">17</xref>). Additionally, studies have shown that SARS-recovered patients can present CD4<sup>+</sup> and CD8<sup>+</sup> T-cells that recognize multiple regions of the N protein; and long-lasting T-cell memory against N protein targets can persist for decades (<xref rid="B18" ref-type="bibr">18</xref>). Thus, the identification of peptide targets from the N protein can support the design of new vaccines and treatments focused on T-cell immune response.</p>
    <p>The state-of-the-art for identifying peptide targets involves the use of computational methods to predict the binding of viral peptides to different HLA receptors. In this sense, sequence-based methods are widely used for this task (<xref rid="B19" ref-type="bibr">19</xref>–<xref rid="B21" ref-type="bibr">21</xref>). However, recent studies have highlighted that the accuracy and sensitivity of sequence-based methods vary widely across HLA alleles (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). One way to improve accuracy/sensitivity would be including peptide-HLA (pHLA) structural features to complement sequence analysis. This was the basis that led to the development of HLA-Arena, a platform that combines sequence- and structure-based analysis of pHLA complexes (<xref rid="B24" ref-type="bibr">24</xref>). The addition of structural information from models obtained using HLA-Arena produced a higher rate of true positive and true negative HLA-binding predictions. HLA-Arena provided a proof-of-concept that both sequence-based and structure-based analyses can be combined into a single, user-friendly computational pipeline, complementing each other into a more reliable and more general consensus prediction. Since different datasets of SARS-CoV-2-peptides have already been identified using sequence-based methods for HLA binding prediction (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>), we expect that a combined approach using sequence and structural methods could be applied for the identification of peptide targets for novel vaccine development.</p>
    <p>Here, we develop SARS-Arena, a pipeline comprised of two workflows that leverages the HLA-Arena environments. Using the first workflow (hereafter called Workflow 1) the user can perform multiple sequence alignment (MSA) of N protein sequences to identify and extract possible peptide targets from conserved regions. Using the second workflow (hereafter called Workflow 2) peptide targets are filtered based on a sequence-based HLA-binding prediction tool. Finally, following the structural modeling of the peptide-HLA complex, we apply a filtering step using well-known scoring functions for structural assessment (<xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>). The output of Workflow 1 is a list of peptides found in conserved regions of N protein from SARS-CoV-2 or SARS-related coronaviruses. In Workflow 2, the output is the three-dimensional model of these peptides sorted according to different scoring functions in the context of different HLAs. We show the advantage of SARS-Arena through a case study to retrieve a well-known immunogenic N peptide and its variants from a set of protein sequences deposited at NCBI.</p>
    <fig position="float" id="f1">
      <label>Figure 1</label>
      <caption>
        <p>In Workflow 1, the input is a set of K protein sequences and the output is a list of peptides found in conserved regions (peptides.list). In Workflow 2, the input is the peptides.list from the previous workflow along with a list of HLA alleles (hlas.list) provided by the user. After using a sequence-based HLA binding affinity prediction tool, the peptides are modeled in the context of the chosen HLA molecules. At the end of Workflow 2 the peptide-HLA structures can be scored according to different scoring functions and the best choices can be presented to the user.</p>
      </caption>
      <graphic xlink:href="fimmu-13-931155-g001" position="float"/>
    </fig>
  </sec>
  <sec sec-type="materials|methods" id="s2">
    <title>2 Materials and Methods</title>
    <p>We used Jupyter Notebook to create two workflows for SARS-Arena. The first workflow (Workflow 1) is designed to allow users to select conserved peptides from N protein MSA. Because the origin of the sequences and the alignment approach can differ, we subdivided Workflow 1 accordingly (see <xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>). The second workflow (Workflow 2) is related to the modeling of conserved peptides in the context of different HLA molecules. To facilitate user experience we created a set of functions that can be accessed from the GitHub repository at <uri xlink:href="https://github.com/KavrakiLab/SARS-Arena">https://github.com/KavrakiLab/SARS-Arena</uri>. SARS-Arena is also made available in a Docker image, which can be downloaded directly from Docker Hub (e.g., using the command line <italic>docker pull kavrakilab/hla-arena:sars-arena</italic>). The following subsections (2.1 to 2.5) will describe the methodologies we use in Workflow 1 and Workflow 2. Then Section 3 concentrates on the results we can obtain using the workflows.</p>
    <fig position="float" id="f2">
      <label>Figure 2</label>
      <caption>
        <p>Overview of Workflows 1 and 2 in SARS-Arena. Workflow 1 is focused on sequence analysis and is organized in three parts: Workflow 1A, 1B, and 1C. Each workflow differs in the way the information is obtained for MSA. At the end of Workflow 1, a list of peptides is generated and can be used in the Workflow 2. Workflow 2 is focused on structural analysis and will return the 3D structure of each peptide in the context of a specific HLA.</p>
      </caption>
      <graphic xlink:href="fimmu-13-931155-g002" position="float"/>
    </fig>
    <sec id="s2_1">
      <title>2.1 SARS-CoV Sequences and Multiple Sequence Alignment</title>
      <p>Workflow 1 can be used to select peptides contained in conserved regions of N protein sequences from SARS-CoV-2 (Workflow 1A and 1B) or SARS-related coronaviruses (Workflow 1C). In Workflow 1A, SARS-CoV-2 protein sequences are retrieved directly from NCBIVirus (<xref rid="B27" ref-type="bibr">27</xref>). In Workflow 1B and 1C, the N protein alignment is already pre-computed. In Workflow 1C, apart from the SARS-CoV-2 sequences, we also used a file with a total of 64 pre-defined N protein sequences from SARS-related coronaviruses. This file was created from information deposited at GenBank and can be augmented with more sequences depending on user needs. For the MSA, we used the MAFFT program (<xref rid="B28" ref-type="bibr">28</xref>) because of its capacity to parallelize jobs during sequence alignment. The time to finalize the alignment task depends on a set of variables, such as the number of sequences to be analyzed, the hardware available to run the alignment, and the number of available cores to be used for the parallel jobs. For this reason, we provide pre-computed MSAs in Workflow 1B and 1C. These MSAs were performed at the NOTS cluster (CRC Rice University) and stored at the Owl Research Infrastructure Open Nebula (ORION) Virtual Machines. The alignments are updated every week so that the users can work with the latest sequences released from NCBI.</p>
    </sec>
    <sec id="s2_2">
      <title>2.2 Conservation Threshold</title>
      <p>In Workflow 1 the user needs to define a scoring method and a scoring matrix so that the level of conservation in the different parts of the aligned K protein sequences is calculated. We provide four different scoring methods - Jensen-Shannon divergence score (<xref rid="B29" ref-type="bibr">29</xref>), Shannon entropy (<xref rid="B30" ref-type="bibr">30</xref>), Property entropy (<xref rid="B31" ref-type="bibr">31</xref>), and Von Neumann entropy (<xref rid="B32" ref-type="bibr">32</xref>). We choose these scoring methods based on a previous publication by Capra and Singh (<xref rid="B33" ref-type="bibr">33</xref>). For scoring matrices, we used the well-known BLOSUM matrices (35, 40, 45, 50, 62, 80, and 100). The conservation cutoff can be modified using a interactive plot at the end of the workflow (<xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>). As conservation values are different and not homogeneous for each position, we provide a Rolling Median Window Length cutoff variable. Alternatively, the user can set the cutoff variable value to 1 to take conservation as it is.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>Interactive plot interface at the end of Workflows 1A, 1B, and 1C. The horizontal line in <bold>(A)</bold> defines a conservation threshold of 80% and in <bold>(B)</bold> a threshold of 85%. The x-axis represents the protein length. The number of peptides will vary according to this threshold, as exemplified by the small tables on the lower right corner of the graph.</p>
        </caption>
        <graphic xlink:href="fimmu-13-931155-g003" position="float"/>
      </fig>
    </sec>
    <sec id="s2_3">
      <title>2.3 Sequence-Based HLA Binding Prediction</title>
      <p>It is known that peptide-HLA binding is mainly driven by sequence features. For this reason, we used MHCflurry 2.0 (<xref rid="B34" ref-type="bibr">34</xref>) to perform a sequence-based HLA binding prediction. We used default parameters to run MHCflurry with a threshold set to 500nM. This value was chosen to recover strong and intermediate HLA peptide binders (<xref rid="B35" ref-type="bibr">35</xref>). Before proceeding, the user can use a interactive plot to modify the 500 nM threshold according to their needs.</p>
    </sec>
    <sec id="s2_4">
      <title>2.4 HLA and Peptide-HLA Modeling</title>
      <p>The sequence to structure conversion occurs in two phases. First, the user needs to input the HLAs of interest in order to pair the peptides obtained from Workflow 1. The name of the HLAs should be contained in a file called <italic>hlas.list</italic> file. We pull the sequences of the user-selected HLA alleles from the EBI database (<xref rid="B36" ref-type="bibr">36</xref>). After that, we use Modeller (<xref rid="B37" ref-type="bibr">37</xref>) to transform the sequence into a three-dimensional structure. We use a homology modeling approach and functions retrieved from HLA-Arena (<xref rid="B24" ref-type="bibr">24</xref>). Since HLAs are highly conserved molecules in terms of sequence and structure, we expect a high accuracy on the generated models. After that, we use APE-Gen (<xref rid="B38" ref-type="bibr">38</xref>) to build the peptide-HLA complex. APE-Gen is a tool that models peptide-HLA complexes using an iterative modeling approach where each iteration contains three key steps. First, the peptide backbone is anchored to HLA pockets (anchor positions) using backbone termini templates. Next, the backbone is completed using a Random Coordinate Descent loop modeling tool (<xref rid="B39" ref-type="bibr">39</xref>) to generate a set of possible backbone conformations. Finally, side chains are added and a local optimization is performed to correct steric clashes. APE-Gen generates an ensemble of conformations, which are all stored for further analysis if desired. By default, however, only the pHLA structure with the lowest energy (i.e., best binding) is selected for subsequent analysis.</p>
    </sec>
    <sec id="s2_5">
      <title>2.5 Scoring Functions</title>
      <p>Binding energy of modeled peptide-HLA structures can be evaluated within Workflow 2 using four integrated scoring functions: AutoDock4 (<xref rid="B40" ref-type="bibr">40</xref>), Vina (<xref rid="B41" ref-type="bibr">41</xref>), Vinardo (<xref rid="B42" ref-type="bibr">42</xref>) and 3pHLA-score (<xref rid="B43" ref-type="bibr">43</xref>). AutoDock4 score is based on an empirical free energy forcefield and is a part of a widely used protein-ligand docking tool. Vina and Vinardo scores are empirical scoring functions. They both originate from the Vina docking tool. The 3pHLA-score is a recently developed scoring function tailored for pHLA structures produced by APE-Gen and based on Rosetta’s ref2015 score (<xref rid="B44" ref-type="bibr">44</xref>). It uses a novel per-peptide-position training approach and consists of per-allele trained modules. It currently supports 28 HLA alleles. The binding energies estimated with the proposed functions are then used to rank the peptides and further refine the list of selected targets. An interactive plot is provided to visualize the scores and allow for dynamic thresholding.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>3 Results</title>
    <p>We created two independent workflows that automatically retrieve peptides located in conserved regions of N protein from SARS-CoV-2 and SARS-related coronaviruses (Workflow 1), and model the three-dimensional structure of these peptides in the context of specific HLAs (Workflow 2) (<xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>). The results we obtain from each workflow are explained in the next sessions.</p>
    <sec id="s3_1">
      <title>3.1 Workflow 1: Sequence Alignment and Peptide Selection</title>
      <p>The first part of SARS-Arena is the sequence alignment and peptide selection, which is coded inside Workflow 1. As described above, we organized this first workflow into three independent parts: Workflow 1A, Workflow 1B, and Workflow 1C. The output of each workflow is the same: a list of peptides obtained from conserved protein regions (<xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>). The different workflows were created to accomodate different inputs.</p>
      <sec id="s3_1_1">
        <title>3.1.1 Workflow 1A</title>
        <p>Workflow 1A allows users to run the MSA of SARS-CoV-2 proteins <italic>in loco</italic>. The maximum limit of sequences to be analyzed will depend on the user’s system hardware. For this reason, we recommend using this workflow when the number of total protein sequences to be analyzed is small (approximately 50,000 sequences). Workflow 1A consists of the following steps. As a preliminary step, the necessary python packages are imported, and the working directories where intermediate files are sorted are also defined. After that, the protein sequences from NCBI Virus are extracted based on a set of parameters. These parameters include choosing (i) the virus strain, (ii) the protein (N protein is the default option), (iii) the completeness of genomes, (iv) the host, (v) the use of only reference sequences or all sequences available, (vi) the geographic region, (vii) the isolation source, (viii) the Pangolin lineage, and (ix) the date of release of sequences. In the second step, the number of protein sequences is shown. In the third step, the program will run the MSA using MAFFT (<xref rid="B28" ref-type="bibr">28</xref>), allowing the use of multiple cores to perform the alignment, optimizing the processing time. Then, a conservation score will be computed based on a scoring method and a BLOSUM matrix. We provide different options in regards to conservation scoring methods and give recommendations of which one to use inside the workflow. The final step of this workflow allows the user to compute and select peptides that belong to conserved regions of the protein alignment. Here SARS-Arena allows the selection of peptides with different lengths using the “min_len” and “max_len” variables. To guide the selection of peptides, we offer an interactive plot interface (<xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>) where the user can set the conservation threshold, the rolling median window length, and the peptide length. The conservation threshold step, the selection of peptides, and the interactive plot interface are the same for Workflows 1A, 1B, and 1C; ergo they are described only in this subsection.</p>
      </sec>
      <sec id="s3_1_2">
        <title>3.1.2 Workflow 1B</title>
        <p>Workflow 1B allows users to recover information from a pre-computed multiple sequence alignment. We recommend the use of this workflow for cases where there is a need to analyze a large number of protein sequences (e.g., more than 50,000 sequences). This workflow consists of three steps. In the first step, after importing the necessary libraries and setting a working directory, the user should set a month and a year to recover the pre-computed alignment. This option is given because there can be differences in the alignments obtained from N protein sequences released on different dates. This pre-computed alignment for each month/year combination is performed every week and stored at Owl Research Infrastructure Open Nebula (ORION) Virtual Machines Pool at Rice University. The Workflow 1B proceeds with the computation of the conservation score and the rest of the steps outlined in Workflow 1A.</p>
      </sec>
      <sec id="s3_1_3">
        <title>3.1.3 Workflow 1C</title>
        <p>Workflow 1C allows the user to analyze the N protein sequences from SARS-related coronaviruses, not only SARS-CoV-2. In the first step, after the initial settings, the user is required to fetch a precomputed MSA alignment, similar to Workflow 1B. After the alignment, a consensus sequence will be printed on the screen and used as input for the next step. In the second step, a new MSA will be performed using as input the consensus sequence from SARS-CoV-2 N protein alignment and a set of predefined N protein sequences (64 in total) from SARS-related coronaviruses obtained from NCBI Protein databank. After the alignment completion, the workflow follows the same final steps of previous workflows, generating a peptide list that can be used in Workflow 2.</p>
      </sec>
    </sec>
    <sec id="s3_2">
      <title>3.2 Workflow 2: Peptide-HLA Prediction for Conserved SARS-CoV-2 Peptides</title>
      <p>Workflow 2 provides a way to model the three-dimensional structure of selected peptides in the context of different HLAs. In the first step the user should provide two files. The first one contains the list of peptides derived from Workflow 1; and the second one with the name of the HLAs written in the format “Gene*Allele group:HLA protein” (e.g., A*02:01 for HLA-A*02:01; C*11:07 for HLA-C*11:07). Since HLA binding depends to some extent on peptide sequence features (<xref rid="B45" ref-type="bibr">45</xref>), in the second step we use MHCflurry to perform initial filtering aiming to keep only good binders for further structural modeling. In this way, we avoid the unnecessary modeling of peptide-HLA that would probably not represent a good target for T-Cell Receptors (TCRs). We set the default cutoff to 500 nM, but this value can be modified according to user needs. In the third step, the three-dimensional HLA structure is created through homology modeling. As the HLA sequence is retrieved from EBI, any HLA can be modeled by our method. In the fourth step, the peptides selected from step 2 are modeled in the context of the chosen HLAs using a pHLA modeling tool called APE-Gen (<xref rid="B38" ref-type="bibr">38</xref>). We know that peptide-binding scoring functions are not completely accurate, but the use of multiple scoring functions can help to overcome this issue (<xref rid="B46" ref-type="bibr">46</xref>). For this reason, in the fifth and final step, we offer the opportunity to rescore the pHLAs generated by APE-Gen using different scoring functions. We added well-known scoring functions - Vina, Vinardo, and AD4 scoring - as well as a new machine learning-based scoring function recently developed, called 3pHLA (<xref rid="B43" ref-type="bibr">43</xref>).</p>
    </sec>
    <sec id="s3_3">
      <title>3.3 Workflow Usage: A Case Study</title>
      <p>A recent study revealed that HLA-B7<sup>+</sup> individuals that recovered from COVID-19 disease triggered a cellular immune response against peptides from SARS-CoV-2 N protein (<xref rid="B47" ref-type="bibr">47</xref>). They identified one immunodominant epitope (SPRWYFYYL, hereafter referred to as SPR) that is conserved across different circulating coronaviruses. To assess if this epitope could be identified and selected by SARS-Arena, we start executing workflows 1A and 1C. The rationale was to generate two different lists of peptides, one from a direct comparison of N protein sequences from SARS-CoV-2 (Workflow 1A) and another one from the comparison of N protein sequences from SARS-related coronaviruses (Workflow 1C). For both workflows, we set an arbitrary conservation threshold of 85%. We were able to retrieve 41 and 17 peptide sequences from workflow 1A and1C, respectively. In the output, the SPR epitope was present in both lists (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Peptides above the conservation threshold of 85% selected from Workflow 1A and 1C.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" colspan="2" align="left" rowspan="1">Workflow 1A</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Workflow 1C</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PQCLPNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKYWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">PQNQRNAPR</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PQGLPNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">QRRPQGLPN</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">`PQGLSNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RRPQGLPNN</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PQVLPNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKHWPQVA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RPQGLPNNT</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PQGVPNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">AYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">PQGLPNNTA</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PQGLPNNTV</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKDWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">QGLPNNTAS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PEGLPNNTA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKRWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GLPNNTASW</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QCLPNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">HYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>SPRWYFYYL</bold>
              </td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QGVPNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKHWSQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">TDYKHWPQI</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QGLPNNTVS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKHWPQIA</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QGLSNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQIAR</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQIAQ</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EGLPNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQIAL</td>
              <td valign="top" align="left" rowspan="1" colspan="1">KHWPQIAQF</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QVLPNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKQWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DAYKTFPPT</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">QGLPNNTAS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQVAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">AYKTFPPTE</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPRWYFYYI</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKTFPPTEP</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>SPRWYFYYL</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKLWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">LPQRQKKQQ</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPRWFFYYL</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKRWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">PQRQKKQQT</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPKWYFYYL</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKDWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">YYKHWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKYWPQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKLWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWSQIAQ</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DYKQWPQIA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>We also wanted to assess if the SPR epitope would be selected at the end of Workflow 2. Since this is an immunodominant epitope, we wanted to be sure SARS-Arena would filter this peptide out and rank it as one of the best peptide targets. For that, we used the peptide list from Workflow 1A and 1C as input to Workflow 2 along with a list of 10 prevalent HLAs (including the HLA-B*07:02 allele). Again, SARS-Arena identified the same epitope SPRWYFYYL described by Lineburg et al. (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>, in bold). Finally, one of the goals of SARS-Arena is also to identify peptide variants from conserved regions that can be used as possible targets in vaccine research. We noted similar sequences to SPRWYFYYL using the list of peptides from Workflow 1A (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). The similarity of sequences, associated with the good HLA sequence-binding prediction and structural binding energy values of these epitopes, could indicate a possible cross-reactive response between these variants and the wild-type SPR epitope. To evaluate this possibility, we decided to use the three-dimensional models generated at the end of Workflow 2 to assess the probability of cross-reactivity based on electrostatic potential patterns from the pHLA surface, as previously described at (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). We included in our analysis an SPR cross-reactive peptide (LPRWYFYYL, hereafter referred to as LPR) and two SPR non-cross-reactive peptides (PPKVHFYYL and SPKLHFYYL, hereafter referred to as PPK and SPK, respectively). Hierarchical clustering analysis revealed that the SPR epitope is more similar to the variants we have found than the known cross-reactive LPR peptide (<xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref>). Also, our analysis correctly separated non-cross-reactive epitopes PPK and SPK indifferent branches. The strong sequence and structure similarity set these variants as putative new targets to be tested towards the development of broad-spectrum T-cell vaccines.</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Identification of an immunodominant epitope in the context of HLA-B*07:02 and its variants. The lower the value the better.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Workflow</th>
              <th valign="top" align="center" rowspan="1" colspan="1">HLA Alelle</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Peptide</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Sequence-based prediction (nM)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Vina (kcal/mol)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Vinardo (kcal/mol)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">AD4 score (kcal/mol)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">p3HLA (nM)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="5" align="left" colspan="1">
                <bold>Workflow 1A</bold>
              </td>
              <td valign="top" rowspan="4" align="center" colspan="1">B*07:02</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>SPRWYFYYL</bold>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">11.37</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-10.88</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-15.11</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-76.67</td>
              <td valign="top" align="center" rowspan="1" colspan="1">101.61</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPRWFFYYL</td>
              <td valign="top" align="center" rowspan="1" colspan="1">14.89</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-9.21</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-12.34</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-75.78</td>
              <td valign="top" align="center" rowspan="1" colspan="1">194.29</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPRWYFYYI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">25.11</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-10.95</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-14.90</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-85.76</td>
              <td valign="top" align="center" rowspan="1" colspan="1">106.00</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPKWYFYYL</td>
              <td valign="top" align="center" rowspan="1" colspan="1">68.47</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-11.23</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-15.69</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-85.54</td>
              <td valign="top" align="center" rowspan="1" colspan="1">100.00</td>
            </tr>
            <tr>
              <td valign="top" align="center" rowspan="1" colspan="1">B*40:01</td>
              <td valign="top" align="left" rowspan="1" colspan="1">YKHWPQIAL</td>
              <td valign="top" align="center" rowspan="1" colspan="1">181.24</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-8.42</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-11.42</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-75.21</td>
              <td valign="top" align="center" rowspan="1" colspan="1">24428.89</td>
            </tr>
            <tr>
              <td valign="top" rowspan="2" align="left" colspan="1">
                <bold>Workflow 1C</bold>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">B*07:02</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>SPRWYFYYL</bold>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">11.37</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-10.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-14.42</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-91.57</td>
              <td valign="top" align="center" rowspan="1" colspan="1">100.00</td>
            </tr>
            <tr>
              <td valign="top" align="center" rowspan="1" colspan="1">A*24:02</td>
              <td valign="top" align="left" rowspan="1" colspan="1">KHWPQIAQF</td>
              <td valign="top" align="center" rowspan="1" colspan="1">258.11</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-8.81</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-12.33</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-74.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1112.68</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>*Immunodominant epitope is highlighted in bold.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>Hierarchical clustering analysis (HCA) and structure comparison of SPR peptide, SPR variants, LPR peptide, and SPK peptide. The TCR-interacting surface is shown in the pHLA complexes and the colors blue, white and red represent positive, neutral, and negative charges, respectively (+3kT to -3kT range). The SPR variants are closer to SPR peptide (wild-type), followed by the known cross-reactive LPR epitope. The non-cross-reactives epitopes SPK and PPK are grouped in a different branch of HCA, probably due to the central positive charge. Numbers in red and green represent the approximately unbiased p-value and the bootstrap probability value, respectively, for each cluster in the dendogram. Here we used the “correlation” as the distance measure and the “average” as the agglomerative method with a total of 100 bootstrap replications.</p>
        </caption>
        <graphic xlink:href="fimmu-13-931155-g004" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>4 Discussion</title>
    <p>The SARS-CoV-2 pandemic highlighted the need for immunoinformatics approaches towards the identification of immunogenic protein targets. At first, the focus was on the humoral immune response. However, as it was recognized that cellular immunity plays an important role complementing or even filling the gap of humoral response, computational methods and databases focused on the prediction and analysis of SARS-CoV-2 T-cell epitopes have been developed (<xref rid="B50" ref-type="bibr">50</xref>–<xref rid="B56" ref-type="bibr">56</xref>). Here we presented SARS-Arena, a user-friendly environment for structure-guided epitope discovery targetting conserved regions of N protein from SARS-CoV-related viruses. SARS-Arena includes two customized workflows. Workflow 1 is focused on (i) fetching protein sequences from NCBI Virus and (ii) selecting of peptides found in conserved regions. Workflow 2 is focused on the three-dimensional modeling of peptides in the context of any HLA molecule. We run Workflow 1 and 2 to evaluate the capacity of SARS-Arena to identify and select epitopes in conserved regions. This analysis returned an immunogenic epitope (SPRWYFYYL) and possible cross-reactive variants. SARS-Arena goes beyond previous efforts by providing an easy-to-use environment for epitope discovery while integrating sequence and structure analysis and targetting conserved regions of SARS-CoV-related proteins.</p>
    <p>The ultimate goal of SARS-Arena was to create a straightforward computational environment to enable epitope discovery efforts by basic, intermediate, and advanced users, while aggregating sequence- and structure-based analysis. Step-by-step workflows are provided as Jupyter Notebooks to be executed alongside tools provided in a Docker image, therefore facilitating the installation process. The workflows and supporting functions can also be modified by the user, to accommodate different computational and data analysis needs. Because SARS-Arena is highly modular and easy to customize, additional steps and functions for advanced practitioners can be implemented as needed.</p>
    <p>We decided to focus SARS-Arena on the N protein because this protein is a promising target for broad-spectrum vaccine development. First, the N gene is more conserved and presents fewer mutations over time (<xref rid="B57" ref-type="bibr">57</xref>). Second, this protein is highly expressed upon infection, increasing the chances for epitopes to be presented to TCR scrutiny in the context of different HLAs (<xref rid="B58" ref-type="bibr">58</xref>). Previous studies have shown that N protein from SARS-CoV is highly immunogenic, and T-cell responses can persist for years after convalescence (<xref rid="B59" ref-type="bibr">59</xref>). Lastly, different regions of the N protein can pass through the intracellular antigen presentation pathway and be presented by a wide range of HLAs, eliciting a dominant cellular immune response (<xref rid="B60" ref-type="bibr">60</xref>). It is important to note that since we expect that some users may want to analyze other SARS-CoV-2 proteins, we also implemented Workflow 1A in a way that any SARS-CoV-2 protein can be analyzed. Finally, advanced users can also modify the provided functions and workflows to apply the same methods to proteins derived from other pathogens of interest.</p>
    <p>Another novelty of SARS-Arena was the inclusion of 3pHLA, a scoring function that uses a per-peptide-position protocol to predict the binding affinity of pHLA complexes. Preliminary results show that 3pHLA outperforms widely used structural scoring functions (manuscript submitted). However, since the 3pHLA scoring relies on machine learning models trained on available binding affinity and structural data, this scoring function is currently restricted to a total of 28 HLA alleles.</p>
    <p>We envision that SARS-Arena can be used as a tool to identify new targets to be used in broad-spectrum therapies. As a proof-of-concept, we decided to run SARS-Arena with a set of predefined parameters and compare the output with targets described in the literature. We focused our analysis on the SPRWYFYYL epitope. This epitope was involved in a dominant T-cell response in HLA-B7<sup>+</sup> individuals, exposed or not to SARS-CoV-2 (<xref rid="B47" ref-type="bibr">47</xref>). In fact, this epitope has already been previously suggested as a SARS-CoV-2 target (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>). SARS-Arena not only was able to recover this peptide but also highlighted the presence of peptide variants in this region. We wonder if these variants could be cross-reactive targets. Surprisingly, in our analysis, the variants are closer to the wild-type peptide than the known cross-reactive target LPR. The analysis of pHLA surface in the context of electrostatic potential charges is robust, validated in previous studies, and has already been used to identify cross-reactive targets to an HCV peptide (<xref rid="B63" ref-type="bibr">63</xref>). Note that the pHLA structural modeling and analysis is crucial for this application since cross-reactivity can occur even among peptides with low sequence similarity and identity. Future studies will be required to fully validate novel targets identified with SARS-arena.</p>
    <p>SARS-Arena can be used to identify and suggest new T-cell targets for SARS-CoV-2 and SARS-CoV-related protein sequences. This environment is simple, but still robust, offering end-to-end workflows to analyze these targets, from raw protein sequences to refined pHLA three-dimensional structures.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>The original contributions presented in the study are included in the article/supplementary materials. Further inquiries can be directed to the corresponding authors.</p>
  </sec>
  <sec sec-type="author-contributions" id="s6">
    <title>Author Contributions</title>
    <p>MR, RF, AC, SH-S, DA, and LK contributed to conception and design of the study. MR wrote the manuscript, compiled the workflows, wrote the documentation, and set up the repository to storage of files. RF implemented the computer codes for Workflow 1, optimized the Workflow 2, and implemented the pre-computed alignments on ORION. AC implemented the computer codes of Workflow 2. LK and DA were responsible for the supervision, project administration, and funding acquisition. All authors contributed to manuscript revision, read, and approved the submitted version.</p>
  </sec>
  <sec sec-type="funding-information" id="s7">
    <title>Funding</title>
    <p>This work was funded in part by the National Science Foundation IIBR: Informatics : RAPID program (2033262) and by Rice University funds. DAA and MMR are supported by a Computational Cancer Biology Training Program fellowship (CPRIT Grant No. RP170593). DAA is also supported in part by University of Houston funds. SHS is supported by a National Library of Medicine Training Program fellowship (T15LM007093-29). LEK is supported in part by NIH U01CA258512.</p>
  </sec>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s9">
    <title>Publisher’s Note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>We thank the Center for Research Computing (CRC) at Rice University for providing the computational environment of Owl Research Infrastructure Open Nebula (ORION) VM Pool.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>SR</given-names></name></person-group>. <article-title>Forty Years With Coronaviruses</article-title>. <source>J Exp Med</source> (<year>2020</year>) <volume>217</volume>(<issue>5</issue>):<elocation-id>e20200537</elocation-id>. doi: <pub-id pub-id-type="doi">10.1084/jem.20200537</pub-id>
<pub-id pub-id-type="pmid">32232339</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Lau</surname><given-names>SK</given-names></name><name><surname>Woo</surname><given-names>PC</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group>. <article-title>Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection</article-title>. <source>Clin Microbiol Rev</source> (<year>2007</year>) <volume>20</volume>(<issue>4</issue>):<page-range>660–94</page-range>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00023-07</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D</given-names></name></person-group>. <article-title>Profile of a Killer: The Complex Biology Powering the Coronavirus Pandemic</article-title>. <source>Nature</source> (<year>2020</year>) <volume>581</volume>(<issue>7806</issue>):<page-range>22–6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/d41586-020-01315-7</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name></person-group>. <article-title>SARS-CoV-2: An Emerging Coronavirus That Causes a Global Threat</article-title>. <source>Int J Biol Sci</source> (<year>2020</year>) <volume>16</volume>(<issue>10</issue>):<page-range>1678–85</page-range>. doi: <pub-id pub-id-type="doi">10.7150/ijbs.45053</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>ZW</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Yuen</surname><given-names>KS</given-names></name><name><surname>Fung</surname><given-names>SY</given-names></name><name><surname>Chan</surname><given-names>CP</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name></person-group>. <article-title>Zoonotic Origins of Human Coronaviruses</article-title>. <source>Int J Biol Sci</source> (<year>2020</year>) <volume>16</volume>(<issue>10</issue>):<page-range>1686–97</page-range>. doi: <pub-id pub-id-type="doi">10.7150/ijbs.45472</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PC</given-names></name><name><surname>Lau</surname><given-names>SK</given-names></name><name><surname>Yip</surname><given-names>CC</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Tsoi</surname><given-names>HW</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><etal/></person-group>. <article-title>Comparative Analysis of 22 Coronavirus HKU1 Genomes Reveals a Novel Genotype and Evidence of Natural Recombination in Coronavirus HKU1</article-title>. <source>J Virol</source> (<year>2006</year>) <volume>80</volume>(<issue>14</issue>):<page-range>7136–45</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00509-06</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Tostanoski</surname><given-names>LH</given-names></name><name><surname>Peter</surname><given-names>L</given-names></name><name><surname>Mercado</surname><given-names>NB</given-names></name><name><surname>McMahan</surname><given-names>K</given-names></name><name><surname>Mahrokhian</surname><given-names>SH</given-names></name><etal/></person-group>. <article-title>DNA Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>(<issue>6505</issue>):<page-range>806–11</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.abc6284</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Development of an Inactivated Vaccine Candidate for SARS-CoV-2</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>(<issue>6499</issue>):<fpage>77</fpage>–<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>
<pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Thao</surname><given-names>TTN</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>Taddeo</surname><given-names>A</given-names></name><name><surname>Ebert</surname><given-names>N</given-names></name><name><surname>Labroussaa</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 Spike D614G Change Enhances Replication and Transmission</article-title>. <source>Nature</source> (<year>2021</year>) <volume>592</volume>(<issue>7852</issue>):<page-range>122–7</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-021-03361-1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Washington</surname><given-names>NL</given-names></name><name><surname>Gangavarapu</surname><given-names>K</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Bolze</surname><given-names>A</given-names></name><name><surname>Cirulli</surname><given-names>ET</given-names></name><name><surname>Schiabor Barrett</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Emergence and Rapid Transmission of SARS-CoV-2 B.1.1.7 in the United States</article-title>. <source>Cell</source> (<year>2021</year>) <volume>184</volume>(<issue>10</issue>):<page-range>2587–94</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.052</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Gilby</surname><given-names>NB</given-names></name><name><surname>Wei</surname><given-names>GW</given-names></name></person-group>. <article-title>Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance</article-title>. <source>J Chem Inf Model</source> (<year>2022</year>) <volume>62</volume>(<issue>2</issue>):<page-range>412–22</page-range>. doi: <pub-id pub-id-type="doi">10.1021/acs.jcim.1c01451</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>WC</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>PH</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Richardus</surname><given-names>JH</given-names></name></person-group>. <article-title>Disappearance of Antibodies to SARS-Associated Coronavirus After Recovery</article-title>. <source>N Engl J Med</source> (<year>2007</year>) <volume>357</volume>(<issue>11</issue>):<page-range>1162–3</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMc070348</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>OW</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Leong</surname><given-names>HN</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Memory T Cell Responses Targeting the SARS Coronavirus Persist Up to 11 Years Post-Infection</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>(<issue>17</issue>):<page-range>2008–14</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.063</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malonis</surname><given-names>RJ</given-names></name><name><surname>Lai</surname><given-names>JR</given-names></name><name><surname>Vergnolle</surname><given-names>O</given-names></name></person-group>. <article-title>Peptide-Based Vaccines: Current Progress and Future Challenges</article-title>. <source>Chem Rev</source> (<year>2020</year>) <volume>120</volume>(<issue>6</issue>):<page-range>3210–29</page-range>. doi: <pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Genome Composition and Divergence of the Novel Coronavirus (2019-Ncov) Originating in China</article-title>. <source>Cell Host Microbe</source> (<year>2020</year>) <volume>27</volume>(<issue>3</issue>):<page-range>325–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id>
</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>NK</given-names></name><name><surname>Mazumdar</surname><given-names>K</given-names></name><name><surname>Gordy</surname><given-names>JT</given-names></name></person-group>. <article-title>The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development</article-title>. <source>J Virol</source> (<year>2020</year>) <volume>94</volume>(<issue>13</issue>):<elocation-id>e00647–20</elocation-id>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00647-20</pub-id>
<pub-id pub-id-type="pmid">32546606</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushal</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>Y</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>Khaiboullina</surname><given-names>SF</given-names></name><name><surname>Baranwal</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>SC</given-names></name></person-group>. <article-title>Mutational Frequencies of SARS-CoV-2 Genome During the Beginning Months of the Outbreak in USA</article-title>. <source>Pathogens</source> (<year>2020</year>) <volume>9</volume>(<issue>7</issue>):<page-range>1–16</page-range>. doi: <pub-id pub-id-type="doi">10.3390/pathogens9070565</pub-id>
</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2-Specific T Cell Immunity in Cases of COVID-19 and SARS, and Uninfected Controls</article-title>. <source>Nature</source> (<year>2020</year>) <volume>584</volume>(<issue>7821</issue>):<page-range>457–62</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>HW</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Mendrick</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Machine Learning Methods for Predicting HLA-Peptide Binding Activity</article-title>. <source>Bioinform Biol Insights</source> (<year>2015</year>) <volume>9</volume>(<issue>Suppl 3</issue>):<page-range>21–9</page-range>. doi: <pub-id pub-id-type="doi">10.4137/BBI.S29466</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>TJ</given-names></name><name><surname>Rubinsteyn</surname><given-names>A</given-names></name><name><surname>Bonsack</surname><given-names>M</given-names></name><name><surname>Riemer</surname><given-names>AB</given-names></name><name><surname>Laserson</surname><given-names>U</given-names></name><name><surname>Hammerbacher</surname><given-names>J</given-names></name></person-group>. <article-title>MHCflurry: Open-Source Class I MHC Binding Affinity Prediction</article-title>. <source>Cell Syst</source> (<year>2018</year>) <volume>7</volume>(<issue>1</issue>):<page-range>129–32</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cels.2018.05.014</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurtz</surname><given-names>V</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Andreatta</surname><given-names>M</given-names></name><name><surname>Marcatili</surname><given-names>P</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name></person-group>. <article-title>NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>199</volume>(<issue>9</issue>):<page-range>3360–8</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1700893</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Sher</surname><given-names>X</given-names></name></person-group>. <article-title>Systematically Benchmarking Peptide-MHC Binding Predictors: From Synthetic to Naturally Processed Epitopes</article-title>. <source>PloS Comput Biol</source> (<year>2018</year>) <volume>14</volume>(<issue>11</issue>):<elocation-id>e1006457</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1006457</pub-id>
<pub-id pub-id-type="pmid">30408041</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonsack</surname><given-names>M</given-names></name><name><surname>Hoppe</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>J</given-names></name><name><surname>Tichy</surname><given-names>D</given-names></name><name><surname>Zeller</surname><given-names>C</given-names></name><name><surname>Küpper</surname><given-names>MD</given-names></name><etal/></person-group>. <article-title>Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC-Peptide Binding Data Set</article-title>. <source>Cancer Immunol Res</source> (<year>2019</year>) <volume>7</volume>(<issue>5</issue>):<page-range>719–36</page-range>. doi: <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-18-0584</pub-id>
</mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>DA</given-names></name><name><surname>Abella</surname><given-names>JR</given-names></name><name><surname>Hall-Swan</surname><given-names>S</given-names></name><name><surname>Devaurs</surname><given-names>D</given-names></name><name><surname>Conev</surname><given-names>A</given-names></name><name><surname>Moll</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy</article-title>. <source>JCO Clin Cancer Inform</source> (<year>2020</year>) <volume>4</volume>:<page-range>623–36</page-range>. doi: <pub-id pub-id-type="doi">10.1200/CCI.19.00123</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun-Jung Lee</surname><given-names>C</given-names></name><name><surname>Koohy</surname><given-names>H</given-names></name></person-group>. <article-title>In Silico Identification of Vaccine Targets for 2019-Ncov</article-title>. <source>F1000Res</source> (<year>2020</year>) <volume>145</volume>:<page-range>1–15</page-range>. doi: <pub-id pub-id-type="doi">10.12688/f1000research.22507.1</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Scheuermann</surname><given-names>RH</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group>. <article-title>A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2</article-title>. <source>Cell Host Microbe</source> (<year>2020</year>) <volume>27</volume>(<issue>4</issue>):<page-range>671–80</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2020.03.002</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatcher</surname><given-names>EL</given-names></name><name><surname>Zhdanov</surname><given-names>SA</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Blinkova</surname><given-names>O</given-names></name><name><surname>Nawrocki</surname><given-names>EP</given-names></name><name><surname>Ostapchuck</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Virus Variation Resource - Improved Response to Emergent Viral Outbreaks</article-title>. <source>Nucleic Acids Res</source> (<year>2017</year>) <volume>45</volume>(<issue>D1</issue>):<page-range>D482–90</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkw1065</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>KD</given-names></name><name><surname>Tomii</surname><given-names>K</given-names></name><name><surname>Katoh</surname><given-names>K</given-names></name></person-group>. <article-title>Parallelization of MAFFT for Large-Scale Multiple Sequence Alignments</article-title>. <source>Bioinformatics</source> (<year>2018</year>) <volume>34</volume>(<issue>14</issue>):<page-range>2490–2</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bty121</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name></person-group>. <article-title>Divergence Measures Based on the Shannon Entropy</article-title>. <source>IEEE Trans Inf Theory</source> (<year>1991</year>) <volume>37</volume>:<page-range>142–51</page-range>. doi: <pub-id pub-id-type="doi">10.1109/18.61115</pub-id>
</mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cover</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name></person-group>. <source>Elements of Information Theory</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley and Sons</publisher-name> (<year>1999</year>).</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirny</surname><given-names>LA</given-names></name><name><surname>Shakhnovich</surname><given-names>EI</given-names></name></person-group>. <article-title>Universally Conserved Positions in Protein Folds: Reading Evolutionary Signals About Stability, Folding Kinetics and Function</article-title>. <source>J Mol Biol</source> (<year>1999</year>) <volume>291</volume>(<issue>1</issue>):<page-range>177–96</page-range>. doi: <pub-id pub-id-type="doi">10.1006/jmbi.1999.2911</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname><given-names>DR</given-names></name><name><surname>Somaroo</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>JD</given-names></name><name><surname>Mintseris</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>ES</given-names></name></person-group>. <article-title>Are Protein-Protein Interfaces More Conserved in Sequence Than the Rest of the Protein Surface</article-title>? <source>Protein Sci</source> (<year>2004</year>) <volume>13</volume>(<issue>1</issue>):<fpage>190</fpage>–<lpage>202</lpage>. doi: <pub-id pub-id-type="doi">10.1110/ps.03323604</pub-id>
<pub-id pub-id-type="pmid">14691234</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capra</surname><given-names>JA</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name></person-group>. <article-title>Predicting Functionally Important Residues From Sequence Conservation</article-title>. <source>Bioinformatics</source> (<year>2007</year>) <volume>23</volume>(<issue>15</issue>):<page-range>1875–82</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btm270</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>TJ</given-names></name><name><surname>Rubinsteyn</surname><given-names>A</given-names></name><name><surname>Laserson</surname><given-names>U</given-names></name></person-group>. <article-title>MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing</article-title>. <source>Cell Syst</source> (<year>2020</year>) <volume>11</volume>(<issue>1</issue>):<page-range>42–8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cels.2020.06.010</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Vitiello</surname><given-names>A</given-names></name><name><surname>Reherman</surname><given-names>B</given-names></name><name><surname>Fowler</surname><given-names>P</given-names></name><name><surname>Nayersina</surname><given-names>R</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes</article-title>. <source>J Immunol</source> (<year>1994</year>) <volume>153</volume>(<issue>12</issue>):<page-range>5586–92</page-range>.</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Buso</surname><given-names>N</given-names></name><name><surname>Gur</surname><given-names>T</given-names></name><name><surname>Madhusoodanan</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The EMBL-EBI Search and Sequence Analysis Tools APIs in 2019</article-title>. <source>Nucleic Acids Res</source> (<year>2019</year>) <volume>47</volume>(<issue>W1</issue>):<page-range>W636–41</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkz268</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>B</given-names></name><name><surname>Sali</surname><given-names>A</given-names></name></person-group>. <article-title>Comparative Protein Structure Modeling Using MODELLER</article-title>. <source>Curr Protoc Protein Sci</source> (<year>2016</year>) <volume>86</volume>:<fpage>1</fpage>–<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpps.20</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abella</surname><given-names>JR</given-names></name><name><surname>Antunes</surname><given-names>DA</given-names></name><name><surname>Clementi</surname><given-names>C</given-names></name><name><surname>Kavraki</surname><given-names>LE</given-names></name></person-group>. <article-title>APE-Gen: A Fast Method for Generating Ensembles of Bound Peptide-MHC Conformations</article-title>. <source>Molecules</source> (<year>2019</year>) <volume>24</volume>(<issue>881</issue>):<page-range>1–13</page-range>. doi: <pub-id pub-id-type="doi">10.3390/molecules24050881</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chys</surname><given-names>P</given-names></name><name><surname>Chacón</surname><given-names>P</given-names></name></person-group>. <article-title>Random Coordinate Descent With Spinor-Matrices and Geometric Filters for Efficient Loop Closure</article-title>. <source>J Chem Theory Comput</source> (<year>2013</year>) <volume>9</volume>(<issue>3</issue>):<page-range>1821–9</page-range>. doi: <pub-id pub-id-type="doi">10.1021/ct300977f</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GM</given-names></name><name><surname>Huey</surname><given-names>R</given-names></name><name><surname>Lindstrom</surname><given-names>W</given-names></name><name><surname>Sanner</surname><given-names>MF</given-names></name><name><surname>Belew</surname><given-names>RK</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><etal/></person-group>. <article-title>AutoDock4 and AutoDockTools4: Automated Docking With Selective Receptor Flexibility</article-title>. <source>J Comput Chem</source> (<year>2009</year>) <volume>30</volume>(<issue>16</issue>):<page-range>2785–91</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group>. <article-title>AutoDock Vina: Improving the Speed and Accuracy of Docking With a New Scoring Function, Efficient Optimization, and Multithreading</article-title>. <source>J Comput Chem</source> (<year>2010</year>) <volume>31</volume>(<issue>2</issue>):<page-range>455–61</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiroga</surname><given-names>R</given-names></name><name><surname>Villarreal</surname><given-names>MA</given-names></name></person-group>. <article-title>Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening</article-title>. <source>PloS One</source> (<year>2016</year>) <volume>11</volume>(<issue>5</issue>):<elocation-id>e0155183</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0155183</pub-id>
<pub-id pub-id-type="pmid">27171006</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conev</surname><given-names>A</given-names></name><name><surname>Devaurs</surname><given-names>D</given-names></name><name><surname>Rigo</surname><given-names>MM</given-names></name><name><surname>Antunes</surname><given-names>AA</given-names></name><name><surname>Kavraki</surname><given-names>LE</given-names></name></person-group>. <article-title>3phla-Score: Structure-Based Peptide-HLA Binding Affinity Prediction</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>(<issue>10749</issue>):<page-range>1–11</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41598-022-14526-x</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leaver-Fay</surname><given-names>A</given-names></name><name><surname>Tyka</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>SM</given-names></name><name><surname>Lange</surname><given-names>OF</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Jacak</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Rosetta3</article-title>. <source>Comput Methods Part C (Elsevier)</source> (<year>2011</year>) <volume>487</volume>:<page-range>545–74</page-range>. doi: <pub-id pub-id-type="doi">10.1016/b978-0-12-381270-4.00019-6</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundegaard</surname><given-names>C</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name></person-group>. <article-title>Accurate Approximation Method for Prediction of Class I MHC Affinities for Peptides of Length 8, 10 and 11 Using Prediction Tools Trained on 9mers</article-title>. <source>Bioinformatics</source> (<year>2008</year>) <volume>24</volume>(<issue>11</issue>):<page-range>1397–8</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btn128</pub-id>
</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>An Overview of Scoring Functions Used for Protein-Ligand Interactions in Molecular Docking</article-title>. <source>Interdiscip Sci</source> (<year>2019</year>) <volume>11</volume>(<issue>2</issue>):<page-range>320–8</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s12539-019-00327-w</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lineburg</surname><given-names>KE</given-names></name><name><surname>Grant</surname><given-names>EJ</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Chatzileontiadou</surname><given-names>DSM</given-names></name><name><surname>Szeto</surname><given-names>C</given-names></name><name><surname>Sloane</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses</article-title>. <source>Immunity</source> (<year>2021</year>) <volume>54</volume>(<issue>5</issue>):<page-range>1055–65</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2021.04.006</pub-id>
</mixed-citation>
    </ref>
    <ref id="B48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>DA</given-names></name><name><surname>Rigo</surname><given-names>MM</given-names></name><name><surname>Silva</surname><given-names>JP</given-names></name><name><surname>Cibulski</surname><given-names>SP</given-names></name><name><surname>Sinigaglia</surname><given-names>M</given-names></name><name><surname>Chies</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Structural in Silico Analysis of Cross-Genotype-Reactivity Among Naturally Occurring HCV NS3-1073-Variants in the Context of HLA-A*02:01 Allele</article-title>. <source>Mol Immunol</source> (<year>2011</year>) <volume>48</volume>(<issue>12–13</issue>):<page-range>1461–7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2011.03.019</pub-id>
</mixed-citation>
    </ref>
    <ref id="B49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname><given-names>MF</given-names></name><name><surname>Antunes</surname><given-names>DA</given-names></name><name><surname>Rigo</surname><given-names>MM</given-names></name><name><surname>Sinigaglia</surname><given-names>M</given-names></name><name><surname>Vieira</surname><given-names>GF</given-names></name></person-group>. <article-title>Improved Structural Method for T-Cell Cross-Reactivity Prediction</article-title>. <source>Mol Immunol</source> (<year>2015</year>) <volume>67</volume>(<issue>2 Pt B</issue>):<page-range>303–10</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2015.06.017</pub-id>
</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Bogdan</surname><given-names>P</given-names></name><name><surname>Nazarian</surname><given-names>S</given-names></name></person-group>. <article-title>An in Silico Deep Learning Approach to Multi-Epitope Vaccine Design: A SARS-CoV-2 Case Study</article-title>. <source>Sci Rep</source> (<year>2021</year>) <volume>11</volume>(<issue>1</issue>):<fpage>3238</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-81749-9</pub-id>
<pub-id pub-id-type="pmid">33547334</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rencilin</surname><given-names>CF</given-names></name><name><surname>Rosy</surname><given-names>JC</given-names></name><name><surname>Mohan</surname><given-names>M</given-names></name><name><surname>Coico</surname><given-names>R</given-names></name><name><surname>Sundar</surname><given-names>K</given-names></name></person-group>. <article-title>Identification of SARS-CoV-2 CTL Epitopes for Development of a Multivalent Subunit Vaccine for COVID-19</article-title>. <source>Infect Genet Evol</source> (<year>2021</year>) <volume>89</volume>:<fpage>104712</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.meegid.2021.104712</pub-id>
<pub-id pub-id-type="pmid">33422682</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behmard</surname><given-names>E</given-names></name><name><surname>Soleymani</surname><given-names>B</given-names></name><name><surname>Najafi</surname><given-names>A</given-names></name><name><surname>Barzegari</surname><given-names>E</given-names></name></person-group>. <article-title>Immunoinformatic Design of a COVID-19 Subunit Vaccine Using Entire Structural Immunogenic Epitopes of SARS-CoV-2</article-title>. <source>Sci Rep</source> (<year>2020</year>) <volume>10</volume>(<issue>1</issue>):<fpage>20864</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-77547-4</pub-id>
<pub-id pub-id-type="pmid">33257716</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Immunodominant Regions Prediction of Nucleocapsid Protein for SARS-CoV-2 Early Diagnosis: A Bioinformatics and Immunoinformatics Study</article-title>. <source>Pathog Glob Health</source> (<year>2020</year>) <volume>114</volume>(<issue>8</issue>):<page-range>463–70</page-range>. doi: <pub-id pub-id-type="doi">10.1080/20477724.2020.1838190</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <label>54</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Toyoshima</surname><given-names>Y</given-names></name><name><surname>Nemoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group>. <article-title>Bioinformatic Prediction of Potential T Cell Epitopes for SARS-Cov-2</article-title>. <source>J Hum Genet</source> (<year>2020</year>) <volume>65</volume>(<issue>7</issue>):<page-range>569–75</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s10038-020-0771-5</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <label>55</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Zha</surname><given-names>Y</given-names></name></person-group>. <article-title>Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1784</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01784</pub-id>
<pub-id pub-id-type="pmid">32849643</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals</article-title>. <source>Cell</source> (<year>2020</year>) <volume>181</volume>(<issue>7</issue>):<page-range>1489–501</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id>
</mixed-citation>
    </ref>
    <ref id="B57">
      <label>57</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Isolation of Virus From a SARS Patient and Genome-Wide Analysis of Genetic Mutations Related to Pathogenesis and Epidemiology From 47 SARS-CoV Isolates</article-title>. <source>Virus Genes</source> (<year>2005</year>) <volume>30</volume>(<issue>1</issue>):<fpage>93</fpage>–<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11262-004-4586-9</pub-id>
<pub-id pub-id-type="pmid">15744567</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>Y</given-names></name><name><surname>Ulasli</surname><given-names>M</given-names></name><name><surname>Schepers</surname><given-names>H</given-names></name><name><surname>Mauthe</surname><given-names>M</given-names></name><name><surname>V’kovski</surname><given-names>P</given-names></name><name><surname>Kriegenburg</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle</article-title>. <source>J Virol</source> (<year>2020</year>) <volume>94</volume>:<elocation-id>e01925–19</elocation-id>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01925-19</pub-id>
<pub-id pub-id-type="pmid">31776274</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>LT</given-names></name><name><surname>Wang</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>ZQ</given-names></name><etal/></person-group>. <article-title>Long-Lived Memory T Lymphocyte Responses Against SARS Coronavirus Nucleocapsid Protein in SARS-Recovered Patients</article-title>. <source>Virology</source> (<year>2006</year>) <volume>351</volume>(<issue>2</issue>):<page-range>466–75</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.virol.2006.03.036</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <label>60</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Baril</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected With SARS Coronavirus</article-title>. <source>PloS One</source> (<year>2006</year>) <volume>1</volume>:<elocation-id>e24</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0000024</pub-id>
<pub-id pub-id-type="pmid">17183651</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Mentzer</surname><given-names>AJ</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>T Cells Induced by SARS-CoV-2 in UK Convalescent Individuals Following COVID-19</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>21</volume>(<issue>11</issue>):<page-range>1336–45</page-range>.</mixed-citation>
    </ref>
    <ref id="B62">
      <label>62</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><name><surname>Choudhury</surname><given-names>S</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A</given-names></name><name><surname>Sakshi</surname><given-names>A</given-names></name><name><surname>Rastogi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2</article-title>. <source>Front Microbiol</source> (<year>2020</year>) <elocation-id>11</elocation-id>:<fpage>1858</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.01858</pub-id>
</mixed-citation>
    </ref>
    <ref id="B63">
      <label>63</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Bakshi</surname><given-names>RK</given-names></name><name><surname>Suneetha</surname><given-names>PV</given-names></name><name><surname>Fytili</surname><given-names>P</given-names></name><name><surname>Antunes</surname><given-names>DA</given-names></name><name><surname>Vieira</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>(<issue>16</issue>):<page-range>8304–17</page-range>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00539-15</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
